INDICATION & USAGE
IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.
Important Safety Information
Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO. Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.
Vaccination with IXIARO may not protect all individuals. Immunocompromised individuals may have a diminished immune response to IXIARO. Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.
The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.
Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967. Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO).
Please see full Prescribing Information.
Learn about the devastating consequences of JE through first-person accounts, as real patients and families affected by JE share their stories.
Japanese Encephalitis (JE)
One vaccine can help protect them4
What is IXIARO®?
IXIARO® is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus for people 2 months of age and older.16
Immune Response Kinetics After Primary Immunization16

IXIARO® has an established safety and tolerability profile16
- The safety of IXIARO® has been confirmed in multiple clinical studies16
- IXIARO® has been used across Europe and the USA since 20094
- Common adverse reactions include fever, irritability, diarrhea, and injection site redness in those up to 1 year of age; fever in children up to age 12, and pain and tenderness in adolescents. In adults the most common side effects are headache, myalgia, and injection site pain and tenderness16
IXIARO® Vaccination Schedule – Accelerated and Standard
- For adults aged 18-65, the vaccine is given in 2 doses, 7 days apart (accelerated schedule) or 28 days apart (standard schedule), and vaccination should be completed 7 days before departure16
- For pediatric (2 months to <18 years) and older adult (66+ years) travelers, the vaccine is given in 2 doses, 28 days apart (standard schedule), and vaccination should be completed 7 days before departure16
- A booster dose (third dose)* may be given at least 11 months after completion of the primary immunization series if ongoing exposure or re-exposure to JE virus is expected16
*Children from 14 months to <3 years of age should receive a single 0.25 mL booster dose. Individuals 3 years of age and older should receive a single 0.5 mL booster dose.16
Vaccination & Travel Timeline16
For travelers preparing a trip to Asia



For more information about
IXIARO® and how to order it visit
Indication & Usage
IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.
Important Safety Information
Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO. Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.
Vaccination with IXIARO may not protect all individuals. Immunocompromised individuals may have a diminished immune response to IXIARO. Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.
The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.
Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967. Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO), or +1-301-556-4500.
Please see full Prescribing Information.
Valneva USA, Inc.
4550 Montgomery Ave.,
Suite 460
Bethesda, MD 20814
USA
Customer Service
+1-833-403-8778
Medical Information
+1 844 349 4276
(8443-IXIARO)
or +1-301-556-4500

This website is intended for US-based healthcare professionals.
US-IXI-2200027 | Copyright © 2022 Valneva USA, Inc. All Rights Reserved.